NEW YORK, June 27, 2023 — NASHNET, a Kinetix Group network of excellence dedicated to advancing care pathways for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), announced the release of an innovative white paper. The paper is titled Biomarkers for Diagnosing and Staging Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Current Perspectives and Potential Future Applications.
Tag: NAFLD
NASHNET Biomarkers White Paper
In support of the Global Liver Institute campaign for International NASH Day, NASHNET developed a groundbreaking white paper titled “Biomarkers for Diagnosing and Staging Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): Current Perspectives and Potential Future Applications.” The white paper sheds light on guideline-directed and optimal use of biomarkers to diagnose or stage NASH. Special thanks… Continue reading NASHNET Biomarkers White Paper
NASHNET Designates Eighth Center of Excellence for Nonalcoholic Steatohepatitis
NEW YORK, January 9, 2020 – Eight leading care delivery systems from across the country have been designated as founding charter members of NASHNET and Centers of Excellence (COEs).
PM360 Announces NASHNET, pioneered by The Kinetix Group, as a Finalist for Its 2019 Trailblazer Award
NEW YORK, August 27, 2019 – NASHNET has been selected as a finalist in the 11th annual PM360 Trailblazer Awards within the Product/Service Launch category. NASHNET is a unique, care delivery model for the treatment of non-alcoholic fatty liver disease (NAFLD) that was founded and launched in 2018 by The Kinetix Group (TKG). TKG has been chosen alongside reputable marketing firms and industry powerhouses for this award.
The Kinetix Group Partners with Rimidi to Launch a Clinical Care Partnership for the Management of Nonalcoholic Steatohepatitis (NASH)
NEW YORK, August 30, 2018 – The Kinetix Group in partnership with Rimidi, an Atlanta-based health care technology firm, announced a partnership focused on improving Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) care delivery leveraging NASHNET, a global centers of excellence network.